Moleculin Biotech (MBRX) to Release Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) will be announcing its earnings results after the market closes on Friday, May 10th. Analysts expect the company to announce earnings of ($3.59) per share for the quarter.

Moleculin Biotech Price Performance

Shares of MBRX stock opened at $4.91 on Thursday. The company’s fifty day moving average price is $6.19 and its 200-day moving average price is $7.86. Moleculin Biotech has a one year low of $4.28 and a one year high of $15.75. The company has a market capitalization of $10.93 million, a price-to-earnings ratio of -0.36 and a beta of 1.85.

Wall Street Analysts Forecast Growth

MBRX has been the subject of a number of research reports. StockNews.com started coverage on Moleculin Biotech in a research report on Tuesday. They set a “sell” rating for the company. Roth Mkm reiterated a “buy” rating and set a $40.00 price objective on shares of Moleculin Biotech in a research report on Friday, April 12th. Finally, Maxim Group reduced their target price on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, March 26th.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.